J&J Unit Sets Funds Aside For Risperdal Settlement

Law360, New York (May 11, 2011, 2:01 PM EDT) -- Johnson & Johnson said in a filing with regulators Tuesday that one of its subsidiaries had reserved money to potentially settle a federal criminal investigation into the off-label promotion of the antipsychotic drug Risperdal.

The reserve Ortho-McNeil-Janssen Pharmaceuticals Inc. recorded for the first quarter of 2011 covers a potential resolution of criminal penalties under the Federal Food, Drug Cosmetic Act over the marketing of the prescription medication used to treat schizophrenia, according to the 10-Q filing with the U.S. Securities and Exchange Commission. The amount of...
To view the full article, register now.